Eli Lilly (LLY)
792.00
+20.25 (2.62%)
NYSE · Last Trade: Jul 16th, 12:37 PM EDT
Detailed Quote
Previous Close | 771.75 |
---|---|
Open | 773.50 |
Bid | 791.18 |
Ask | 792.75 |
Day's Range | 772.16 - 796.04 |
52 Week Range | 677.09 - 972.53 |
Volume | 1,714,517 |
Market Cap | 757.61B |
PE Ratio (TTM) | 64.44 |
EPS (TTM) | 12.3 |
Dividend & Yield | 6.000 (0.76%) |
1 Month Average Volume | 2,945,716 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
Via Benzinga · July 16, 2025
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via Benzinga · July 16, 2025
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.
Via MarketBeat · July 15, 2025
PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market
PolyPid Ltd. (NASDAQ: PYPD), a late-stage biopharma company with a market cap of just $35 million, has unveiled a potentially transformative approach to the red-hot GLP-1 market that could significantly disrupt how weight loss and diabetes medications are delivered to patients.
Via AB Newswire · July 15, 2025
Palatin’s Oral Obesity Drug Shows Remarkable Results: The Hidden Gem in the Weight Loss Race
Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) may have just positioned itself as a serious contender in the rapidly expanding obesity treatment market with impressive new preclinical data for its oral MC4R agonist PL7737. The results, announced today, demonstrate both rapid weight loss as a standalone therapy and enhanced effects when combined with GLP-1 medications like tirzepatide.
Via AB Newswire · July 15, 2025
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Via StockStory · July 15, 2025
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.
Via Benzinga · July 14, 2025
An update on Sana Biotechnology.
Via Benzinga · July 14, 2025
Rocket Lab notched its fastest launch turnaround ever, completing its 68th Electron mission and signaling a new era of rocket deployment.
Via Benzinga · July 14, 2025
Via Benzinga · July 11, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via Benzinga · July 11, 2025
Eli Lilly stock has risen over 400% in 5 years despite a recent pullback.
Via Talk Markets · July 10, 2025
Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories.
Via MarketBeat · July 10, 2025
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Via StockStory · July 10, 2025
Via The Motley Fool · July 9, 2025
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady.
Via Benzinga · July 9, 2025
Reuters reported on Wednesday, citing three sources, that Starlink has cleared the only remaining regulatory hurdle for the satellite provider to enter the market.
Via Stocktwits · July 9, 2025
Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid plaque reduction.
Via Benzinga · July 9, 2025
The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less pathologically advanced in their disease.
Via Stocktwits · July 9, 2025
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation.
Via Stocktwits · July 8, 2025